Long Non-coding RNA PCED1B Antisense RNA 1 Promotes Cell Proliferation and Invasion in Hepatocellular Carcinoma by Regulating the MicroRNA-34a/CD44 Axis

Abstract

Objective

This study aimed to examine the role of long non-coding RNA PCED1B antisense RNA 1 (PCED1B-AS1) in the development of hepatocellular carcinoma (HCC).

Methods

A total of 62 pairs of HCC tissues and adjacent non-tumor tissues were obtained from 62 HCC patients. The interactions of PCED1B-AS1 and microRNA-34a (miR-34a) were detected by dual luciferase activity assay and RNA pull-down assay. The RNA expression levels of PCED1B-AS1, miR-34a and CD44 were detected by RT-qPCR, and the protein expression level of CD44 was determined by Western blotting. The cell proliferation was detected by cell proliferation assay, and the cell invasion and migration by transwell invasion assay. The HCC tumor growth after PCED1B-AS1 was downregulated was determined by in vivo animal study.

Results

PCED1B-AS1 was highly expressed in HCC tissues, which was associated with poor survival of HCC patients. Furthermore, PCED1B-AS1 interacted with miR-34a in HCC cells, but they did not regulate the expression of each other. Additionally, PCED1B-AS1 increased the expression level of CD44, which was targeted by miR-34a. The cell proliferation and invasion assay revealed that miR-34a inhibited the proliferation and invasion of HCC in vitro, while CD44 exhibited the opposite effects. Furthermore, PCED1B-AS1 suppressed the role of miR-34a. Moreover, the knockdown of PCED1B-AS1 repressed the HCC tumor growth in nude mice in vivo.

Conclusion

PCED1B-AS1 may play an oncogenic role by regulating the miR-34a/CD44 axis in HCC.

Keywords

long non-coding RNA PCED1B antisense RNA 1 (PCED1B-AS1) / hepatocellular carcinoma / microRNA-34a (miR-34a) / CD44 / proliferation / invasion

References

[1] GhouriYA, MianI, RoweJH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog, 2017, 16: 1

[2] BrayF, FerlayJ, SoerjomataramI, et al.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424

[3] MominBR, PinheiroPS, CarreiraH, et al.. Liver cancer survival in the United States by race and stage (2001–2009): Findings from the CONCORD-2 study. Cancer, 2017, 123(Suppl24): 5059-5078

[4] Maucort-BoulchD, de MartelC, FranceschiS, et al.. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer, 2018, 142(12): 2471-2477

[5] BertuccioP, TuratiF, CarioliG, et al.. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol, 2017, 67(2): 302-309

[6] OgholikhanS, SchwarzKB. Hepatitis Vaccines. Vaccines (Basel), 2016, 4(1): 6

[7] CastelliG, PelosiE, TestaU. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel), 2017, 9(9): 127

[8] Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169(7): 1327-1341

[9] KudoM. Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets, 2012, 12(9): 1062-1072

[10] SaweyET, ChanrionM, CaiC, et al.. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell, 2011, 19(3): 347-358

[11] SpizzoR, AlmeidaMI, ColombattiA, et al.. Long non-coding RNAs and cancer: a new frontier of translational research?. Oncogene, 2012, 31(43): 4577-4587

[12] QiP, DuX. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol, 2013, 26(2): 155-165

[13] WeiL, WangX, LvL, et al.. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer, 2019, 18: 1-11

[14] ZhanT, GaoX, WangG, et al.. Construction of Novel lncRNA-miRNA-mRNA Network Associated With Recurrence and Identification of Immune-Related Potential Regulatory Axis in Hepatocellular Carcinoma. Front Oncol, 2021, 11: 626663

[15] YangJ, YuD, LiuX, et al.. LncRNA PCED1B-AS1 activates the proliferation and restricts the apoptosis of glioma through cooperating with miR-194-5p/PCED1B axis. J Cell Biochem, 2020, 121(2): 1823-1833

[16] LiuC, KelnarK, LiuB, et al.. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med, 2011, 17(2): 211-215

[17] SunT, XieH, LiZ, et al.. miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma. Am J Transl Res, 2017, 9(1): 103-114

[18] LiN, FuH, TieY, et al.. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett, 2009, 275(1): 44-53

[19] GougeletA, SartorC, BachelotL, et al.. Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut, 2016, 65(6): 1024-1034

[20] LiuC, KelnarK, LiuB, et al.. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med, 2011, 17(2): 211-215

[21] SchmittgenT, LivakK. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc, 2008, 3(6): 1101-1108

[22] FengY, WeiG, ZhangL, et al.. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis. Bioengineered, 2021, 12(1): 8217-8232

[23] JiangMC, NiJJ, CuiWY, et al.. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res, 2019, 9(7): 1354-1366

[24] LiC, YangJ, LiuC, et al.. Long non-coding RNAs in hepatocellular carcinoma: ordering of the complicated lncRNA regulatory network and novel strategies for HCC clinical diagnosis and treatment. Pharmacol Res, 2020, 158: 104848

[25] FabregatI, RonceroC, FernandezM. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int, 2007, 27(2): 155-162

[26] LiN, FuH, TieY, et al.. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett, 2009, 275(1): 44-53

[27] ZhangJ, LouWJF. A key mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network linked to diagnosis and prognosis of hepatocellular carcinoma. Front Oncol, 2020, 10: 340

[28] TangC, FengW, BaoY, et al.. Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP). Bioengineered, 2021, 12(1): 2119-2131

[29] YangY, ShiL, ZhangD, et al.. Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1). Bioengineered, 2021, 12(1): 6713-6723